Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines

Table 2 IC₅₀ values of chemotherapeutic agents on CCA cell lines.

Drug	IC50 (mmol/L)
	Poorly differentiated		Moderately differentiated		Well differentiated
	KKU-100	KKU-M055	KKU-M156	KKU-M214	KKU-OCA17
Anthracyclins
Doxorubicin	2.3±0.8b	0.04±0.02	1.8±1.0b	0.25±0.05	0.84±0.83
Pirarubicin	0.27±0.22a	0.01±0.01	0.35±0.06b	0.17±0.03b	0.13±0.05b
Platinum derivatives
Cisplatin	37±3b	0.05±0.01	222±38b	130±12b	6.22±0.19b
Carboplatin	13±3b	0.26±0.01	229±36b	107±4b	10.4±2.7a
Oxaliplatin	71.7±38.7a	0.11±0.00	7.0±4.7	38.0±6.7b	6.8±1.3b
Pyrimidine analog
5-Fluorouracil	1 018±326d	46±42c	144±55d	29.1±17.6b	3.46±0.91
Taxanes
Paclitaxel	39.0±6.8b	0.0030±0.0001	10.9±5.8a	2.62±0.75a	12.5±1.9b
Docetaxel	41.2±7.2b	0.00002±0.00002	0.80±0.36a	12.4±3.7a	1.3±0.3b
Vinca-alkaloids
Vincristine	216.2±52.1d	2.05±0.68c	0.97±0.64	85±19d	0.82±0.17
Vinorabine	2.1±0.2b	0.13±0.01	0.23±0.01a	164±120	0.64±0.17a
Others
Etoposide	416±131b	0.04±0.01	274±217b	54±26a	126±88a
Irinotecan	23±6a	3.41±0.51	13.1±2.1b	43±9b	3.60±1.16
Mitomycin C	45±2b	0.01±0.00	187±0b	78±32a	5.07±0.17b

Data represents mean±SD of at least three experiments.

^aP<0.05,

^bP<0.01 vs KKU-M055;

^cP<0.05,

^dP<0.01 vs KKU-OCA17.